GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Biohaven Ltd.
Following the sale of its blockbuster migraine drug to Pfizer, Biohaven shares represent a bet on a new chapter in the company's history. The price trajectory reflects investors' faith in the team's ability to replicate its success and develop new drugs for the treatment of neurological diseases.
Share prices of companies in the market segment - Neuro
Biohaven shares, following the sale of its blockbuster migraine drug, are betting on a new chapter. Its core segment is neuroscience. We classify it as the Neuro sector, and the chart below shows the dynamics of the entire segment, where the value depends on the success of clinical trials.
Broad Market Index - GURU.Markets
Biohaven is a biopharmaceutical company focused on developing treatments for neurological and rare diseases. Its innovations earn it a spot in the GURU.Markets index. The chart below represents the market. See how clinical trial successes impact Biohaven shares.
Change in the price of a company, segment, and market as a whole per day
BHVN - Daily change in the company's share price Biohaven Ltd.
The change_co indicator for Biohaven, a biopharmaceutical company, measures its high volatility. It reflects its sensitivity to news about clinical trials of its neuroscience drugs. This indicator is a key component of formulas on System.GURU.Markets for risk analysis in the biotech sector.
Daily change in the price of a set of shares in a market segment - Neuro
Biohaven Ltd. is a biotech company. This chart highlights the sector's extreme volatility. Comparison with BHVN, which focuses on neuroscience, helps us assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Biohaven is a biopharmaceutical company specializing in drugs for the treatment of neurological diseases. Neurology is a risky field of research. The chart below illustrates the high volatility typical of the biotech sector, reflecting the stakes associated with Biohaven's developments.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Biohaven Ltd.
Biohaven is a biotech company working on treatments for neurological diseases. Its shares represent a venture-backed bet on scientific success. Their high volatility, driven by expectations, contributes to the complex and multifaceted dynamics of the overall stock market.
Annual dynamics of market capitalization of the market segment - Neuro
Biohaven Ltd. is a biopharmaceutical company focused on developing drugs for the treatment of neurological diseases. Following the sale of its successful migraine drug, its goal is to prove the value of its new R&D. The chart below shows how the market perceives the potential of its scientific platform and future growth.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Biohaven is a biopharmaceutical company whose stock performance is driven by the success of its drug sales and progress in research. The company's business is not dependent on economic cycles. The chart reflects biotech events rather than macroeconomic data, making it a non-cyclical growth story.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Biohaven Ltd.
Biohaven, a biopharmaceutical company focused on neurological diseases, has monthly fluctuations reflecting news about the clinical trials of its new drugs, particularly after the sale of its successful migraine drug to Pfizer, which provided it with significant capital for R&D.
Monthly dynamics of market capitalization of the market segment - Neuro
Biohaven is a biopharmaceutical company specializing in developing drugs to treat neurological diseases such as migraine and Alzheimer's disease. This is one of the most complex areas of medicine. The chart below illustrates the overall dynamics of the neurological development sector, which carries both high risks and potential rewards.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Biohaven is a biopharmaceutical company focused on neuroscience. Following the sale of its blockbuster drug, its value is now entirely dependent on the success of new developments in its portfolio. Its stock price is unrelated to the market and represents a venture bet on future breakthroughs in the treatment of brain diseases.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Biohaven Ltd.
The weekly performance of Biohaven, a biopharmaceutical company focused on neurological diseases, reflects the search for treatments for migraines and other disorders. Share prices react sharply to clinical trial results and the commercial success of their drugs.
Weekly dynamics of market capitalization of the market segment - Neuro
Neuroscience-focused biotech is a sector where weekly performance is driven by clinical trial data. Breakthroughs or failures in migraine or Alzheimer's treatments influence sentiment across the industry. The chart provides this backdrop against which Biohaven's portfolio can be assessed.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Biohaven is a biotech company focused on neurological diseases. Its success depends on the results of clinical trials and the commercialization of its drugs. This chart will help you understand: does Biohaven live in its own world of scientific news, or are the overall market conditions and risk appetite in biotech actually influencing its stock price?
Market capitalization of the company, segment and market as a whole
BHVN - Market capitalization of the company Biohaven Ltd.
Biohaven's market capitalization chart is a success story of developing a new class of migraine drugs, which led to the sale of a key asset to Pfizer. Its current performance is the market's attempt to evaluate the company's "second act": its new developments in neurology and immunology, financed by the proceeds.
BHVN - Share of the company's market capitalization Biohaven Ltd. within the market segment - Neuro
Biohaven is a biotech company focused on developing drugs for the treatment of neurological and rare diseases. Its market share reflects the success of its previous company, which was sold to Pfizer, and the potential of its current pipeline. Its market capitalization reflects the team's proven ability to create blockbusters.
Market capitalization of the market segment - Neuro
Biohaven is a biopharmaceutical company focused on developing drugs for neurological diseases. The chart below shows the overall market capitalization of this complex sector. Its dynamics reflect the high risks and potentially enormous rewards of developing breakthrough treatments for migraines, epilepsy, and other diseases.
Market capitalization of all companies included in a broad market index - GURU.Markets
Biohaven is a biotech company focused on developing drugs for the treatment of neurological and rare diseases. Its market capitalization reflects the potential of its scientific portfolio. The chart below shows the economic weight of companies at the forefront of neuroscience.
Book value capitalization of the company, segment and market as a whole
BHVN - Book value capitalization of the company Biohaven Ltd.
Biohaven's book value is its capital dedicated to the development and commercialization of drugs for the treatment of neurological and rare diseases. This is a tangible, scientific foundation, built on the success of previous developments and aimed at new discoveries. How has this asset changed? The chart below shows its dynamics.
BHVN - Share of the company's book capitalization Biohaven Ltd. within the market segment - Neuro
Biohaven, focused on neurological diseases, utilizes cutting-edge R&D laboratories to develop its drugs. The chart shows the share of these science-intensive tangible assets in the pharmaceutical sector, reflecting the physical foundation of its innovations in the treatment of migraines and other disorders.
Market segment balance sheet capitalization - Neuro
Biopharma, as the BCap_Seg chart shows, requires investment in science. Biohaven is an interesting case. After selling its blockbuster, the company refocused on R&D. The chart helps us understand that its current model is a science-intensive, rather than an industrial-capital-intensive, business.
Book value of all companies included in the broad market index - GURU.Markets
Biohaven's balance sheet isn't based on its production capacity, but rather on a vast portfolio of patents and clinical developments in neuroscience. Its value is the capitalization of an intellectual asset that, if successful, will translate into tangible drugs capable of changing the lives of millions of patients.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Biohaven Ltd.
Biohaven is a biotech company focused on neurological diseases. Its book value is small, and its market capitalization is a valuation of its scientific developments and potential blockbusters. BHVN's MvsBCap chart will be highly volatile, as any success or failure in clinical trials could dramatically alter its future valuation.
Market to book capitalization ratio in a market segment - Neuro
Biohaven Ltd. is a biopharmaceutical company specializing in neurological disorders. Its value is determined by its pipeline and successful clinical trials. This metric reflects the market's appreciation of its scientific potential and future blockbusters, rather than its current assets.
Market to book capitalization ratio for the market as a whole
Biohaven Ltd. is a biotech company focused on neurological diseases. Its valuation depends almost entirely on the success of its R&D program and the potential of future drugs. For such companies, book value means little. The chart illustrates how investors are betting on a scientific breakthrough in one of the most complex areas of medicine.
Debts of the company, segment and market as a whole
BHVN - Company debts Biohaven Ltd.
Biohaven, a biopharmaceutical company focused on neurological disorders, is raising capital to fund its extensive clinical programs. Developing drugs for conditions like migraine and Alzheimer's requires billions of dollars in investment. This chart shows how the company funds its ambitious research.
Market segment debts - Neuro
Biohaven is a biopharmaceutical company specializing in developing treatments for neurological and rare diseases. The journey from lab to pharmacy requires significant financial resources. Debt is a key part of its clinical trial funding strategy. This chart provides insight into how Biohaven manages its capital.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Biohaven Ltd.
Biohaven is a biotech company specializing in neurological disorders. The chart shows its financial structure. For a company investing hundreds of millions in clinical trials of new drugs, capital management is critical. The debt level reflects its reliance on external funding to advance its research.
Market segment debt to market segment book capitalization - Neuro
Biohaven develops drugs for neurological diseases, which requires significant investment in clinical research. This biotech industry chart illustrates how the sector as a whole finances the long and risky path from lab to pharmacy. It provides context for assessing the company's financial strategy and sustainability.
Debt to book value of all companies in the market
Biohaven is a biotech company. Its funding depends on investors' confidence in future drugs. This chart reflects the overall risk appetite in the economy. For a company without revenue, it helps understand how its debt- or equity-based financing model compares to the overall market.
P/E of the company, segment and market as a whole
P/E - Biohaven Ltd.
This chart for Biohaven, a biopharmaceutical company specializing in neurological diseases, reflects investor expectations for its pipeline. High values indicate market confidence in the success of clinical trials and the commercial potential of new drugs for migraines, Alzheimer's, and other disorders.
P/E of the market segment - Neuro
This chart shows the average P/E ratio for the biopharmaceutical industry in which Biohaven operates. The sector's high valuation reflects expectations for new blockbusters. This metric serves as a benchmark for understanding how Biohaven's neuroscience pipeline is valued by the market compared to other companies in development.
P/E of the market as a whole
Biohaven Ltd. is a biopharmaceutical company specializing in developing treatments for neurological and rare diseases. Its success depends on the results of clinical trials. This chart, showing investors' overall risk appetite, is an indicator of their willingness to invest in Biohaven's long-term and uncertain R&D projects in hopes of a breakthrough.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Biohaven Ltd.
Biohaven is a biopharmaceutical company specializing in drugs for the treatment of neurological and rare diseases. The chart shows investor expectations for the success of its clinical developments. Future developments depend entirely on research results and regulatory approvals for new promising drugs.
%20P%2FE%20Biohaven%20Ltd.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Biohaven-Ltd.&v=1772697222743 "Chart of the company's future (projected) P/E Biohaven Ltd.")
Future (projected) P/E of the market segment - Neuro
Biohaven Ltd. is a biopharmaceutical company specializing in neurological and rare diseases. Its success depends on the results of clinical trials and the launch of new drugs. Average profitability expectations for the segment are shown here. This allows us to assess how highly the market values the scientific potential of Biohaven's developments.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Neuro&v=1772697222772 "Future (projected) P/E graph of the market segment - Neuro")
Future (projected) P/E of the market as a whole
Biohaven Ltd. is a biopharmaceutical company specializing in the treatment of neurological and rare diseases. Its value is determined by its development pipeline and the success of clinical trials. This chart of overall market sentiment shows how much investors are prepared to tolerate the risk associated with long-term investments in biotechnology.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772697222787 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Biohaven Ltd.
Biohaven Ltd. is a biopharmaceutical company focused on developing treatments for neurological and rare diseases. Its financial performance is determined by the success of clinical trials and the commercialization of its drugs. This chart shows the company's path from significant investments in research to the potential for high profits from the sale of innovative drugs.
Profit of companies in the market segment - Neuro
Biohaven Ltd. is a biopharmaceutical company specializing in developing treatments for neurological and rare diseases. Its success depends on clinical trial results and drug approvals. This chart shows the overall profitability dynamics in the neurological pharmaceutical segment, where the need for new drugs is enormous, but the development risks are also very high.
Overall market profit
Biohaven Ltd. is a biopharmaceutical company focused on neurological and rare diseases. Its success is determined by scientific developments and clinical trial results. The company's future depends on the approval and commercialization of its drugs, not on short-term economic cycles, as can be seen in this chart. It is a classic example of an innovative company.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Biohaven Ltd.
Biohaven Ltd. is a biopharmaceutical company specializing in the treatment of neurological and rare diseases. Its future profitability depends on the success of clinical trials and the commercialization of new drugs. This chart reflects analyst expectations regarding the potential of the company's product portfolio, especially following the sale of its blockbuster migraine drug.
%20profit%20of%20the%20company%20Biohaven%20Ltd.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Biohaven-Ltd.&v=1772697222829 "Graph of future (projected) profit of the company Biohaven Ltd.")
Future (predicted) profit of companies in the market segment - Neuro
Biohaven Ltd. is a biopharmaceutical company specializing in developing treatments for neurological and rare diseases. Its success depends on the results of clinical trials and the ability to bring new drugs to market. This chart shows overall revenue projections for the entire neurological pharmaceutical segment, allowing one to assess the potential of Biohaven's development pipeline.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Neuro&v=1772697222841 "Graph of future (predicted) profits of companies in a market segment - Neuro")
Future (predicted) profit of the market as a whole
Biohaven Ltd. is a biopharmaceutical company specializing in developing treatments for neurological and rare diseases. Its value depends on progress in drug development. The overall economic environment, reflected in this chart, influences investors' risk appetite and their willingness to finance long-term biotech projects.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772697222878 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Biohaven Ltd.
Biohaven is a biopharmaceutical company specializing in neurological diseases. Following the sale of its blockbuster migraine drug, the company is focusing on new developments. This chart shows how investors value its current clinical pipeline and future revenue potential, not past sales.
P/S market segment - Neuro
Biohaven is a biopharmaceutical company focused on developing treatments for neurological and rare diseases. Their strategy is to discover and develop promising molecules to accelerate the availability of new medicines for patients. This chart reflects the average revenue estimate for the sector, providing insight into market expectations for Biohaven's pipeline.
P/S of the market as a whole
Biohaven Ltd. is a biopharmaceutical company focused on developing treatments for neurological and rare diseases. Its success depends on the results of clinical trials. This chart highlights that for research-stage companies, valuations are loosely tied to current revenue and more closely reflect the potential of their research, which contrasts with the market average.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Biohaven Ltd.
Biohaven Ltd. is a biopharmaceutical company specializing in developing treatments for neurological and rare diseases. For a company whose success depends on clinical trial results, valuation based on future revenue is key. It reflects investor expectations regarding potential blockbusters in its pipeline and the likelihood of their approval and commercialization.
%20P%2FS%20Biohaven%20Ltd.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Biohaven-Ltd.&v=1772697222927 "The graph of the company's future (projected) P/S Biohaven Ltd.")
Future (projected) P/S of the market segment - Neuro
Biohaven is a biopharmaceutical company specializing in developing treatments for neurological and rare diseases. This chart compares the company's estimated future sales with industry expectations. It shows how investors view its pipeline, particularly following the successful launch of its migraine drug, and its ability to bring new innovative drugs to market.
%20P%2FS%20market%20segment%20graph%20-%20Neuro&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Neuro&v=1772697222936 "Future (projected) P/S market segment graph - Neuro")
Future (projected) P/S of the market as a whole
Biohaven is a biopharmaceutical company focused on neurological diseases. Its success depends on the results of clinical trials and the launch of new drugs. In the context of the overall revenue forecasts shown in the chart, Biohaven represents a sector that is driving future growth through science.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772697222941 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Biohaven Ltd.
This chart shows the revenue of Biohaven, a biopharmaceutical company specializing in developing treatments for neurological and rare diseases. Revenue is generated from sales of its commercial products and partnerships. The dynamics of this indicator reflect the success of drug commercialization and progress in clinical trials of new molecules.
Sales of companies in the market segment - Neuro
Biohaven Ltd. is a biopharmaceutical company focused on neurological diseases. Following the sale of its blockbuster migraine treatment, the company is developing new drugs. The future sales mix will determine which of its pipeline candidates can replicate this success, demonstrating the company's ability to innovate and generate new revenue streams.
Overall market sales
Biohaven Ltd. is a biopharmaceutical company specializing in the treatment of neurological diseases. Its future depends on the success of clinical development and the approval of new drugs. This market overview chart provides context for a company whose value is created in the laboratory and determined by its ability to alleviate patient suffering, not by economic trends.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Biohaven Ltd.
Biohaven Ltd. is a biopharmaceutical company specializing in the development of treatments for neurological and rare diseases. Its future revenue depends on the results of clinical trials and the successful launch of new drugs. This chart illustrates analysts' forecasts for potential sales of drugs in Biohaven's pipeline, reflecting their commercial potential.
%20sales%20of%20the%20company%20Biohaven%20Ltd.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Biohaven-Ltd.&v=1772697222978 "Schedule of future (projected) sales of the company Biohaven Ltd.")
Future (projected) sales of companies in the market segment - Neuro
Biohaven Ltd. is a biopharmaceutical company specializing in developing treatments for neurological and rare diseases. This chart shows sales forecasts for the entire biotech sector. What are analysts' expectations for the market for drugs for migraines and other disorders? This sets the overall tone for Biohaven.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Neuro&v=1772697222985 "Schedule of future (projected) sales of companies in the market segment - Neuro")
Future (projected) sales of the market as a whole
Biohaven Ltd. is a biopharmaceutical company specializing in developing treatments for neurological and rare diseases. Its success is determined by scientific advances, clinical trial results, and regulatory approvals. The general economic trends reflected in this chart have little impact on the fundamental drivers of the company's value.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772697222989 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Biohaven Ltd.
Biohaven Ltd. is a biopharmaceutical company specializing in developing treatments for neurological and rare diseases. This chart shows its financial path from research to market. The company's profitability is determined by the success of its clinical programs and its ability to commercialize innovative drugs that can transform the lives of patients with severe disorders.
Market segment marginality - Neuro
Biohaven Ltd. is a biopharmaceutical company specializing in the development of drugs for the treatment of neurological diseases. Following the sale of its successful migraine drug, the company is focusing on developing new candidates in its pipeline. This chart reflects the company's financial performance during the R&D phase, where profitability is the goal and depends on the success of clinical trials.
Market marginality as a whole
Biohaven Ltd. is a biopharmaceutical company focused on neurological disorders. Its value is determined by the potential of its drugs and the success of clinical trials. This total return chart reflects investors' risk appetite. In a strong economy, investors are more inclined to fund innovative but capital-intensive biopharmaceuticals.
Employees in the company, segment and market as a whole
Number of employees in the company Biohaven Ltd.
Biohaven is a biotech company focused on neurological diseases. Following the sale of its blockbuster migraine treatment, it is rebuilding its team to develop new drugs. This chart shows the staffing dynamics during this transition period, when the company invests in new research and clinical programs, building a team for future products.
Share of the company's employees Biohaven Ltd. within the market segment - Neuro
Biohaven is a biopharmaceutical company specializing in developing treatments for neurological and rare diseases. Its core activities are focused on research and clinical trials. This chart shows the company's market share in the biotech industry, and its dynamics reflect its progress in developing new drugs and attracting scientific talent.
Number of employees in the market segment - Neuro
Biohaven Ltd. is a biopharmaceutical company specializing in developing treatments for neurological and rare diseases. This chart shows employment trends in neuroscience. Growth in this sector reflects a growing understanding of the brain and investments in the fight against diseases such as migraine and Alzheimer's, where Biohaven strives to offer new solutions.
Number of employees in the market as a whole
Biohaven is a biopharmaceutical company specializing in the treatment of neurological diseases, particularly migraine. The growth of its scientific and marketing team reflects the commercial success of its drugs. Unlike the overall employment in this chart, hiring dynamics at Biohaven depend on clinical trial results and regulatory approvals.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Biohaven Ltd. (BHVN)
Biohaven is a biotech company focused on neurological diseases. This chart shows how the market values their research. A huge market cap can be built on the success of a single drug. The high number on the chart reflects the value of intellectual property, not current sales or a large workforce.
%20of%20the%20company%20Biohaven%20Ltd.%20(BHVN)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Biohaven-Ltd.-BHVN&v=1772697223066 "Chart of market capitalization per employee (in thousands of dollars) of the company Biohaven Ltd. (BHVN)")
Market capitalization per employee (in thousands of dollars) in the market segment - Neuro
Biohaven (BHVN) is a biotech company that (following the sale of its blockbuster Nurtec) has focused on developing new drugs for neurological and rare diseases. This chart shows the average market cap per employee in the sector. It helps assess how the market values their R&D portfolio and team of scientists (funded by the sale of Nurtec).
%20by%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Neuro&v=1772697223072 "Market capitalization per employee (in thousands of dollars) by market segment - Neuro")
Market capitalization per employee (in thousands of dollars) for the overall market
Biohaven is a biopharmaceutical company focused on neurological diseases. Its success is driven by the development and commercialization of innovative drugs. The chart shows a high employee value, typical for successful biotech companies. The market evaluates the value of intellectual property and future revenue streams from patented drugs.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772697223088 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Biohaven Ltd. (BHVN)
Biohaven is a biotech company focused on neurological diseases. The company is known for developing migraine treatments. This chart shows how successfully the company commercializes its R&D achievements. It reflects how much revenue the team (scientists, doctors, and marketers) generates from the sale of its innovative drugs.
%20Chart%20Biohaven%20Ltd.%20(BHVN)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Biohaven-Ltd.-BHVN&v=1772697223099 "Company Profit Per Employee (in thousands of dollars) Chart Biohaven Ltd. (BHVN)")
Profit per employee (in thousands of dollars) in the market segment - Neuro
Biohaven (BHVN) is an R&D biotech (neurology, migraine). This chart shows the benchmark for "Neuro" (R&D). The average profit per employee in this sector (venture R&D) is *negative* (or high if there is one hit). The benchmark reflects the "burning" of cash in the hopes of one or two mega-successes.
%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Neuro&v=1772697223106 "Chart of profit per employee (in thousands of dollars) in the market segment - Neuro")
Profit per employee (in thousands of dollars) for the market as a whole
Biohaven Ltd. is a biopharmaceutical company focused on neuroscience. (They spun out of Pfizer after selling their blockbuster migraine drug.) They're an R&D company. This chart shows the capital burn (loss per employee)—the cost of developing a new drug portfolio after the sale of the core asset, calculated per team of scientists.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772697223115 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Biohaven Ltd. (BHVN)
Biohaven is a biopharmaceutical company focused on neurological diseases. This graph shows the commercial potential of their research and development. After a successful drug is launched, revenue per employee increases sharply, reflecting the high cost of innovation and the ability of a small team of scientists to create a blockbuster.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Biohaven-Ltd.-BHVN&v=1772697223121 "Sales chart per company employee Biohaven Ltd. (BHVN)")
Sales per employee in the market segment - Neuro
Biohaven Ltd. is a biotech company focused on neuroscience (e.g., migraine) and rare diseases. They are known for selling their blockbuster to Pfizer. This chart shows the average yield in the sector. For BHVN, this is an indicator of the effectiveness of their R&D model: how productive is their team of scientists in creating new "blockbusters" and generating revenue (through sales or acquisitions)?
Sales per employee for the market as a whole
Biohaven is a biotech company focused on neurological disorders. After selling their blockbuster migraine drug, they refocused on R&D. This indicator reflects their current phase: the company is investing in science, and revenue (if any) is likely to come from partnerships rather than mass sales.
Short shares by company, segment and market as a whole
Shares shorted by company Biohaven Ltd. (BHVN)
Biohaven (BHVN) is a biotech company focused on neurological and rare diseases. The company gained notoriety after selling its migraine drug to Pfizer. This chart shows the number of bearish bets. Shorts may reflect doubts that the remaining drugs in development (the pipeline) will be able to replicate past success.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Biohaven-Ltd.-BHVN&v=1772697223150 "Short Shares Chart for the Company Biohaven Ltd. (BHVN)")
Shares shorted by market segment - Neuro
Biohaven (BHVN) is a biopharmaceutical company specializing in the treatment of neurological and rare diseases (known for its migraine drug). This chart aggregates short positions in the neuroscience biotech sector. It reflects the high level of risk and investor skepticism regarding the complexity of brain drug development.
Shares shorted by the overall market
Biohaven (BHVN) is a neuroscience-focused biotech. This indicator (`Short_All`) is a mirror of market fear. When it rises, investors panic and shed risk. Biotech stocks, even those with approved drugs, often suffer sell-offs when general pessimism rules the market.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Biohaven Ltd. (BHVN)
Biohaven (BHVN) is a biopharmaceutical company focused on neurological and rare diseases. They became known for developing migraine drugs, selling part of their business to Pfizer. This chart is a momentum oscillator. It shows when the excitement around their new R&D pipeline peaks (above 70) or when investors take profits, leading to an oversold market (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Biohaven-Ltd.-BHVN&v=1772697223174 "RSI 14 indicator chart for the company's stock Biohaven Ltd. (BHVN)")
RSI 14 Market Segment - Neuro
Biohaven (BHVN) is a biotech company focused on neuroscience. The RSI_14_Seg for "Neuro" (biotech) shows the overall sentiment. The chart helps us understand: is BHVN's volatility a reaction to its clinical trials, or is the entire biotech sector overheated (or oversold) on expectations?
RSI 14 for the overall market
Biohaven (BHVN) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an easy way to raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast BHVN (Biohaven Ltd.)
Biohaven Ltd. is a biotech company best known for developing the migraine drug Nurtec ODT, which was sold to Pfizer. The company is now using the proceeds to develop a new portfolio of neurology drugs. This chart shows the average analyst forecast based on their assessment of their new clinical programs and their large cash reserves.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-BHVN-Biohaven-Ltd.&v=1772697223211 "A chart showing analyst consensus forecasts for the expected stock price. BHVN (Biohaven Ltd.)")
The difference between the consensus estimate and the actual stock price BHVN (Biohaven Ltd.)
Biohaven is a biotech company (a spinoff from the older Biohaven, which was sold to Pfizer). They are focused on developing drugs for neurological and rare diseases, using royalty revenue from their successful migraine drug. This chart shows how analysts evaluate their new R&D pipeline and future clinical data.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-BHVN-Biohaven-Ltd.&v=1772697223220 "A chart showing the difference between the consensus forecast and the actual stock price. BHVN (Biohaven Ltd.)")
Analyst consensus forecast for stock prices by market segment - Neuro
Biohaven is a biopharmaceutical company that was reborn after the sale of its blockbuster migraine drug (Nurtec) to Pfizer. It is now focusing on a new portfolio of neurology and immunology drugs. This chart shows analysts' overall expectations for the neurology sector, reflecting whether experts believe the team can replicate its success.
Analysts' consensus forecast for the overall market share price
Biohaven Ltd. is a biopharmaceutical company focused on neuroscience. Their strategy is to develop drugs for migraines, epilepsy, and other brain disorders. This chart shows overall market sentiment. For Biohaven, as an R&D company, it's important to understand how overall risk appetite (analyst sentiment) influences funding for their expensive research in the complex field of neuroscience. (349)
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Biohaven Ltd.
Biohaven (BHVN) is a biotech focused on the most complex area of neuroscience (migraine, CNS). This is the second iteration of the company, created after the mega-deal of selling their first blockbuster to Pfizer. This chart represents an R&D bet. It reflects the market's belief that their team will be able to catch lightning in a bottle a second time, using their capital for new discoveries.
AKIMA Market Segment Index - Neuro
Biohaven (BHVN) is a biotech incubator created (following the sale of Nurtec to Pfizer) to develop a new pipeline of drugs, primarily in neuroscience. This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does this R&D model (funded by the sale of Nurtec) differentiate Biohaven from the average pharma company?
The AKIM Index for the overall market
Biohaven is a biopharmaceutical company focused on neuroscience and immunology. It is known for developing migraine treatments (Nurtec was sold to Pfizer, and now it's developing a new portfolio). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this R&D story compares to overall economic trends.
